Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adverse Drug Event Clear all
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Adalimumab, Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
12
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Reducing Concurrent Opioid-Benzodiazepine Prescriptions

NCT03887247
View directory record Official record
Conditions
Adverse Drug Effect of Opioids, Adverse Drug Effect of Benzodiazepines
Interventions
E-mail Alert
Behavioral
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
2,234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole

NCT04903353
View directory record Official record
Conditions
Weight Gain, Autism Spectrum Disorder, Medication Side Effect
Interventions
Comparison of Risperidone and Aripiprazole
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Not listed Not applicable Interventional

Improving Geriatric Drug Safety in Underserved Practices

NCT00277173
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Adoption of Crew Resource Management approach
Behavioral
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
65 Years and older
Enrollment
4,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2006 · Synced Sep 9, 2026, 1:32 PM EDT
Not listed Phase 1 Interventional

Post IVIG Medication in Children With Immune Thrombocytopenia

NCT04741139
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Acetaminophen and Diphenhydramine Only Product
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced Sep 9, 2026, 1:32 PM EDT
Terminated Phase 4 Interventional

Pain Control After Minimally Invasive Coronary Artery Bypass Grafting

NCT01770236
View directory record Official record
Conditions
Postoperative Pain, Medication Side Effects, Narcotic Requirement
Interventions
IV acetaminophen
Drug
Lead sponsor
Gundersen Lutheran Medical Foundation
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Sep 9, 2026, 1:32 PM EDT
Completed No phase listed Observational Results available

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

NCT04682587
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Axitinib, Avelumab, Pembrolizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Sep 9, 2026, 1:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Reduction of Adverse Drug Events and Readmissions

NCT02738047
View directory record Official record
Conditions
Pharmacogenomic Testing for Medication Management
Interventions
Not listed
Lead sponsor
ClinLogic LLC
Industry
Eligibility
25 Years and older
Enrollment
280,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

Regional Data Exchange to Improve Care for Veterans After Non-VA Hospitalization

NCT02689076
View directory record Official record
Conditions
Patient Readmission, Adverse Drug Event, Cost
Interventions
HIE Notification, Care transitions intervention
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Phase 3 Interventional

Sleep, Fatigue, and Dexamethosone in Children With Leukemia

NCT00075101
View directory record Official record
Conditions
Leukemia
Interventions
Dexamethosone
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
5 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 17, 2008 · Synced Sep 9, 2026, 1:32 PM EDT
Recruiting Phase 3 Interventional

Melatonin for Prevention of Kidney Injury

NCT05084196
View directory record Official record
Conditions
Acute Kidney Injury, Adverse Drug Event
Interventions
Melatonin, Placebo Capsule
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey • Somerville, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

NCT05476679
View directory record Official record
Conditions
Submental Fat
Interventions
RZL-012, RZL-012+Lidacaine injection prior treatment, RZL-012+Medrol, RZL-012+Celecoxib+Zyrtec, RZL-012+facial and neck wrap
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine

NCT04818515
View directory record Official record
Conditions
Migraine
Interventions
Atogepant, Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Orlando, Florida • Springfield, Missouri • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing the Detection and Management of Adverse Drug Events in Nursing Homes

NCT01531088
View directory record Official record
Conditions
Adverse Drug Events
Interventions
Active medication monitoring
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Study the Feasibility and Acceptability of an App to Support Pediatric Resuscitation

NCT06768099
View directory record Official record
Conditions
Pediatric Emergency Medicine, Resuscitation, Pediatrics, Emergency Medical Services, Arrest Cardio Respiratory
Interventions
Linear Cognitive Aid
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Comparison of Recurrence of Atrial Fibrillation Post Cryoballon Ablation During the 90-day Blanking Period-with and Without Anti-arrhythmic Drug Therapy

NCT02913014
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
No AAD post Ablation.
Other
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 9, 2026, 1:32 PM EDT
Not yet recruiting Not applicable Interventional

AIManage Using an AI-driven CDS and Chatbot

NCT07546357
View directory record Official record
Conditions
Diabetes, Obesity, Medication Side Effects
Interventions
AIManage
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PK of Depo SubQ Injected in the Upper Arm

NCT01143207
View directory record Official record
Conditions
Contraception
Interventions
Medroxyprogesterone acetate
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2013 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

NCT03251144
View directory record Official record
Conditions
HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
Interventions
Switch to E/C/FTC/TAF daily
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

NCT00076323
View directory record Official record
Conditions
Glucosephosphate Dehydrogenase Deficiency, Favism
Interventions
Primaquine
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Sep 9, 2026, 1:32 PM EDT
Completed No phase listed Observational

Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)

NCT04181775
View directory record Official record
Conditions
Adverse Drug Event
Interventions
ADE-RED scoring tool
Diagnostic Test
Lead sponsor
Methodist Health System
Other
Eligibility
Not listed
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 9, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography

NCT01475097
View directory record Official record
Conditions
Drug Safety
Interventions
Iodixanol, Iopamidol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 9, 2026, 1:32 PM EDT
Active, not recruiting Phase 2 Interventional

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

NCT04305145
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event
Interventions
Infliximab, Methylprednisolone, Prednisone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 9, 2026, 1:32 PM EDT